Bay­er nabs star biotech Vi­vid­ion with a $2B buy­out and an ‘arms-length’ pact, pulling a part­ner out of the IPO con­ga line

Vi­vid­ion is can­cel­ing that IPO it filed. In­stead of fol­low­ing the in­dus­try-wide mi­gra­tion to Nas­daq, the biotech that has cap­tured con­sid­er­able at­ten­tion for its …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER